TR-1: NOTIFICATION OF MAJOR INTEREST INSHARESi
|
i |
||||
|
||||
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii |
ConvaTec Group PLC |
|||
2 Reason for the notification (please tick the appropriate box or boxes): |
||||
An acquisition or disposal of voting rights |
|
|||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
|||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
|||
An event changing the breakdown of voting rights |
|
|||
Other (please specify): |
Corrective Filing - See Item 13 |
|
X |
|
3. Full name of person(s) subject to the notification obligation: iii |
OrbiMed Advisors LLC and OrbiMed Capital LLC |
|||
4. Full name of shareholder(s) (if different from 3.):iv |
OrbiMed Partners Master Fund Limited OrbiMed Partners II, L.P. OrbiMed Global Healthcare Master Fund, L.P. Stichting Depositary APG Developed Markets Equity Pool Worldwide Healthcare Trust PLC |
|||
5. Date of the transaction and date on which the threshold is crossed or reached: v |
October 26, 2016 |
|||
6. Date on which issuer notified: |
October 28, 2016 |
|||
7. Threshold(s) that is/are crossed or reached: vi, vii |
Not applicable |
|||
8. Notified details: |
||||||||||||||||
A: Voting rights attached to shares viii, ix |
||||||||||||||||
Class/type of shares
if possible using the ISIN CODE |
Situation previous to the triggering transaction |
Resulting situation after the triggering transaction |
||||||||||||||
Number of Shares |
Number of Voting Rights |
Number of shares |
Number of voting rights |
% of voting rights x |
||||||||||||
Direct |
Direct xi |
Indire ct xii |
Direct |
Indirect |
||||||||||||
GB00BD3VFW73 |
0 |
0 |
23,000,000 |
23,000,000 |
0 |
1.18% |
0 |
|||||||||
|
||||||||||||||||
B: Qualifying Financial Instruments |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial instrument |
Expiration date xiii |
Exercise/ Conversion Period xiv |
Number of voting rights that may be acquired if the instrument is exercised/ converted. |
% of voting rights |
||||||||||||
|
|
|
|
|
||||||||||||
|
||||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial instrument |
Exercise price |
Expiration date xvii |
Exercise/ Conversion period xviii |
Number of voting rights instrument refers to |
% of voting rights xix, xx |
|||||||||||
|
|
|
|
|
Nominal |
Delta |
||||||||||
|
|
|||||||||||||||
|
||||||||||||||||
Total (A+B+C) |
||||||||||||||||
Number of voting rights |
Percentage of voting rights |
|||||||||||||||
23,000,000 |
1.18% |
|||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi |
||
|
||
|
||
Proxy Voting: |
||
10. Name of the proxy holder: |
|
|
11. Number of voting rights proxy holder will cease to hold: |
|
|
12. Date on which proxy holder will cease to hold voting rights: |
|
|
|
||
13. Additional information: |
OrbiMed Advisors LLC and OrbiMed Capital LLC (together, "OrbiMed") are affiliated investment advisers registered with the U.S. Securities and Exchange Commission. OrbiMed acts as investment manager or investment adviser for the funds and accounts listed in Item 4, which beneficially own the shares that are the subject of this notification.
This filing (the "New Filing") is being submitted to correct the TR-1 submitted on October 28, 2016 (the "Prior Filing"), as it has been determined that the Prior Filing was filed mistakenly due to a calculation error. The Prior Filing inadvertently identified the 23,000,000 shares referenced in Item 8.A as constituting 3.49% of the voting rights related to the issuer's issued share capital. In fact, the 23,000,000 shares constituted only 1.18% of such voting rights. As a result, no TR-1 filing was actually required, but OrbiMed considers it appropriate to update the market in this way. OrbiMed is submitting the New Filing, with the corrected percentages in the relevant parts of Item 8, to correct the Prior Filing as of the date thereof. |
|
14. Contact name: |
Douglas Coon |
|
15. Contact telephone number: |
1-212-739-6400 |
|